Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022.
Summary of Fourth Quarter and Recent Highlights
- Revenue of $24.0 million, an increase of 6% year-over-year
- GAAP EPS of $(0.02), non-GAAP EPS of $(0.10)
- Successful first patient use Sublime™ .018 RX PTA Dilatation Catheter
“We’re extremely pleased to share that the Sublime™ and Pounce™ clinical product evaluations are confirming the meaningful advantages of our radial access and arterial thrombectomy products,” said Gary Maharaj, President and CEO of Surmodics, Inc. “Our fiscal 2022 promises to be an exciting year as we accelerate the commercialization of our innovative radial access, thrombectomy and drug-coated balloon platforms.”
Fourth Quarter Fiscal 2021 Financial Results
Total revenue for the fourth quarter of fiscal 2021 was $24.0 million, compared to $22.5 million in the prior-year period. Medical Device revenue was $17.4 million for the fourth quarter of fiscal 2021, compared to $17.2 million for the prior-year period, an increase of 1%. Medical Device revenue in the fourth quarter of fiscal 2021 includes $1.2 million from our Development and Distribution Agreement with Abbott Vascular, Inc. (“Abbott”) for the SurVeil™ drug-coated balloon, compared to $1.6 million in the prior-year quarter. In Vitro Diagnostics revenue was $6.6 million for the fourth quarter of fiscal 2021, compared to $5.4 million in the same prior-year quarter, an increase of 23%.
Diluted GAAP earnings per share in the fourth quarter of fiscal 2021 was a loss per share of $(0.02), compared to a loss per share of $(0.22) in the prior-year period. On a non-GAAP basis, loss per share in the fourth quarter of fiscal 2021 was $(0.10), compared to a loss per share of $(0.18) in the same prior-year quarter. On a non-GAAP basis, adjusted net loss and adjusted EPS exclude a $2.6 million and $0.19 per share tax-effected benefit, respectively, recorded in the fourth quarter of fiscal 2021 related to the reimbursement of certain expenses under the employee retention credit provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act").
As of September 30, 2021, Surmodics reported cash and investments totaling $40.9 million and $10 million in outstanding borrowings on its $25 million line of credit. Surmodics reported $0.9 million of cash provided by operating activities and $2.4 million in capital expenditures in the fourth quarter of fiscal 2021. Surmodics completed its acquisition of Vetex Medical Limited during the fourth quarter of fiscal 2021, with the upfront cash payment of $39.9 million funded using cash on hand and $10 million from the Company’s $25 million line of credit.
Fiscal 2022 Guidance
Surmodics has the potential to receive a $30 million milestone payment during fiscal 2022 related to premarket approval of the SurVeil DCB pursuant to the Abbott Development and Distribution Agreement. The potential revenue associated with this milestone payment would be approximately $25 million. As has been the Company’s practice with past guidance, revenue from regulatory-related milestones is not included in guidance until they are achieved.
Surmodics expects fiscal year 2022 revenue to range from $97 million to $101 million. The Company expects fiscal 2022 diluted GAAP EPS to range from a loss per share of $(2.05) to $(1.55), which reflects increased investments to accelerate the Company’s strategy. Non-GAAP diluted EPS for fiscal 2022 is expected to range from a loss per share of $(1.75) to $(1.25).
Conference Call Today at 7:30 a.m. CT (8:30 a.m. ET)
Surmodics is hosting a webcast at 7:30 a.m. CT (8:30 a.m. ET) today to discuss fourth quarter results. To access the webcast, go to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com and click on the webcast icon. The webcast will be archived on the Company’s website for 90 days. A replay of the fourth quarter conference call will be available by dialing 888-203-1112 and entering conference call ID passcode 2633660. The audio replay will be available beginning at 10:30 a.m. CT on Wednesday, November 10, 2021, until 10:30 a.m. CT on Wednesday, November 17, 2021.
About Surmodics, Inc.
Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the Company makes with the Securities and Exchange Commission (“SEC”).
Safe Harbor for Forward-looking Statements
This press release, and disclosures related to it, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical or current facts, including statements regarding the Company’s revenue and loss expectations for fiscal 2022; expectations regarding acceleration of the commercialization of the Company’s radial access, thrombectomy and drug-coated balloon platforms; expectations regarding design verification, process validation, and manufacturing validation related to the Company’s products; our fiscal 2022 objectives; expectations regarding expansion of the potential range of uses of the Company’s products; the potential market position of the Company’s products; the anticipated fiscal 2022 full-year license revenue associated with the Development and Distribution Agreement with Abbott; expectations regarding FDA premarket review timing and process and the potential approval of our SurVeil DCB; the potential receipt of a premarket approval milestone payment from Abbott; the expected timing of completion and delivery of the SWING first-in-human clinical trial results; the potential of the Company’s products and fiscal 2022 activities to create long-term value; the Company’s strategy; plans for clinical product evaluations; the anticipated reimbursement under CARES Act Employee Retention Credit; expectations regarding revenue from our Sublime and Pounce product portfolios and growth in the value of those portfolios; and expectations regarding fiscal 2022 revenue growth, operating expenses and tax expense, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including, without limitation: (1) our ability to successfully develop and commercialize our SurVeil DCB (including realization of the full potential benefits of our agreement with Abbott), Avess™ DCB, Sundance™ DCB, and other proprietary products; (2) whether and when the FDA grants premarket approval to the SurVeil DCB; (3) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market, and sell products incorporating our technologies; (4) possible adverse market conditions and possible adverse impacts on our cash flows; (5) the impacts, duration, and severity of the global COVID-19 pandemic and the effects of responses to it on healthcare systems, the general economy, our business partners, and our operations; (6) our ability to integrate the acquisition of Vetex Medical Limited successfully and realize the anticipated benefits of the acquisition; and (7) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and subsequent SEC filings. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.
Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with U.S. generally accepted accounting principles, or GAAP, Surmodics is reporting non-GAAP financial results including EBITDA and Adjusted EBITDA, non-GAAP operating (loss) income, non-GAAP operating (loss) income percentage, non-GAAP (loss) income before income taxes, non-GAAP net (loss) income, non-GAAP diluted (loss) earnings per share, and the non-GAAP effective income tax rate. We believe that these non-GAAP measures, when read in conjunction with the Company’s GAAP financial statements, provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payouts under our executive compensation programs. We also are providing guidance on a range of non-GAAP diluted loss per share for fiscal 2022. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact on our reported financial results. As such, these non-GAAP measures should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.
Surmodics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (Unaudited) |
|||||||||||||||
|
Three Months Ended |
|
Fiscal Year Ended |
||||||||||||
|
September 30, |
|
September 30, |
||||||||||||
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||||||
|
|
|
|
|
|
||||||||||
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales |
$ |
12,509 |
|
|
$ |
10,586 |
|
|
$ |
46,478 |
|
|
$ |
44,317 |
|
Royalties and license fees |
|
8,874 |
|
|
|
9,867 |
|
|
|
47,056 |
|
|
|
40,634 |
|
Research, development and other |
|
2,588 |
|
|
|
2,090 |
|
|
|
11,602 |
|
|
|
9,913 |
|
Total revenue |
|
23,971 |
|
|
|
22,543 |
|
|
|
105,136 |
|
|
|
94,864 |
|
Operating costs and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product costs |
|
4,159 |
|
|
|
3,902 |
|
|
|
17,177 |
|
|
|
15,317 |
|
Research and development |
|
10,731 |
|
|
|
12,787 |
|
|
|
46,734 |
|
|
|
50,188 |
|
Selling, general and administrative |
|
7,865 |
|
|
|
7,300 |
|
|
|
30,680 |
|
|
|
28,392 |
|
Acquired intangible asset amortization |
|
1,117 |
|
|
|
547 |
|
|
|
2,793 |
|
|
|
2,218 |
|
Acquisition transaction, integration and other costs |
|
588 |
|
|
|
— |
|
|
|
1,049 |
|
|
|
— |
|
Total operating costs and expenses |
|
24,460 |
|
|
|
24,536 |
|
|
|
98,433 |
|
|
|
96,115 |
|
Operating (loss) income |
|
(489 |
) |
|
|
(1,993 |
) |
|
|
6,703 |
|
|
|
(1,251 |
) |
Other expense, net |
|
(73 |
) |
|
|
(85 |
) |
|
|
(357 |
) |
|
|
(203 |
) |
(Loss) income before income taxes |
|
(562 |
) |
|
|
(2,078 |
) |
|
|
6,346 |
|
|
|
(1,454 |
) |
Income tax benefit (provision) |
|
273 |
|
|
|
(868 |
) |
|
|
(2,109 |
) |
|
|
2,577 |
|
Net (loss) income |
$ |
(289 |
) |
|
$ |
(2,946 |
) |
|
$ |
4,237 |
|
|
$ |
1,123 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic (loss) income per share: |
$ |
(0.02 |
) |
|
$ |
(0.22 |
) |
|
$ |
0.31 |
|
|
$ |
0.08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted (loss) income per share: |
$ |
(0.02 |
) |
|
$ |
(0.22 |
) |
|
$ |
0.30 |
|
|
$ |
0.08 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
13,851 |
|
|
|
13,639 |
|
|
|
13,765 |
|
|
|
13,552 |
|
Diluted |
|
13,851 |
|
|
|
13,639 |
|
|
|
13,989 |
|
|
|
13,812 |
|
Surmodics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands) |
||||||||
|
|
September 30, |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Assets |
|
|
|
|||||
Current Assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
31,153 |
|
|
$ |
30,785 |
|
Available-for-sale securities |
|
|
7,717 |
|
|
|
30,313 |
|
Accounts receivable, net |
|
|
9,169 |
|
|
|
7,675 |
|
Contract assets — royalties and license fees |
|
|
7,091 |
|
|
|
6,108 |
|
Inventories, net |
|
|
6,760 |
|
|
|
5,966 |
|
Prepaids and other |
|
|
8,365 |
|
|
|
5,761 |
|
Total Current Assets |
|
|
70,255 |
|
|
|
86,608 |
|
Property and equipment, net |
|
|
30,090 |
|
|
|
30,103 |
|
Available-for-sale securities |
|
|
2,002 |
|
|
|
— |
|
Deferred income taxes |
|
|
5,867 |
|
|
|
7,315 |
|
Intangible assets, net |
|
|
37,054 |
|
|
|
13,283 |
|
Goodwill |
|
|
45,606 |
|
|
|
27,185 |
|
Other assets |
|
|
3,718 |
|
|
|
4,269 |
|
Total Assets |
|
$ |
194,592 |
|
|
$ |
168,763 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Short-term borrowings |
|
|
10,000 |
|
|
|
— |
|
Deferred revenue |
|
|
4,647 |
|
|
|
5,200 |
|
Other current liabilities |
|
|
15,168 |
|
|
|
13,692 |
|
Total Current Liabilities |
|
|
29,815 |
|
|
|
18,892 |
|
Deferred revenue |
|
|
10,301 |
|
|
|
10,796 |
|
Other long-term liabilities |
|
|
14,391 |
|
|
|
8,020 |
|
Total Liabilities |
|
|
54,507 |
|
|
|
37,708 |
|
Total Stockholders’ Equity |
|
|
140,085 |
|
|
|
131,055 |
|
Total Liabilities and Stockholders’ Equity |
|
$ |
194,592 |
|
|
$ |
168,763 |
|
|
|
|
|
|
|
|
|
|
Surmodics, Inc. and Subsidiaries Supplemental Segment Information (in thousands) (Unaudited) |
||||||||||||||||||||
|
|
Three Months Ended September 30, |
|
|
|
|
|
|||||||||||||
|
|
2021 |
|
|
2020 |
|
|
|
|
|
||||||||||
Revenue: |
|
|
|
|
|
% of Total |
|
|
|
|
|
|
% of Total |
|
|
% Change |
|
|||
Medical Device |
|
$ |
17,395 |
|
|
72.6% |
|
|
$ |
17,179 |
|
|
76.2% |
|
|
1.3% |
|
|||
In Vitro Diagnostics |
|
|
6,576 |
|
|
27.4% |
|
|
|
5,364 |
|
|
23.8% |
|
|
22.6% |
|
|||
Total revenue |
|
$ |
23,971 |
|
|
|
|
|
|
$ |
22,543 |
|
|
|
|
|
|
6.3% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ended September 30, |
|
|
|
|
|
|||||||||||||
|
|
2021 |
|
|
2020 |
|
|
|
|
|
||||||||||
Revenue: |
|
|
|
|
|
% of Total |
|
|
|
|
|
|
% of Total |
|
|
% Change |
|
|||
Medical Device |
|
$ |
78,253 |
|
|
74.4% |
|
|
$ |
71,401 |
|
|
75.3% |
|
|
9.6% |
|
|||
In Vitro Diagnostics |
|
|
26,883 |
|
|
25.6% |
|
|
|
23,463 |
|
|
24.7% |
|
|
14.6% |
|
|||
Total revenue |
|
$ |
105,136 |
|
|
|
|
|
|
$ |
94,864 |
|
|
|
|
|
|
10.8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Fiscal Year Ended |
|
|
|
||||||||||||
|
|
September 30, |
|
|
September 30, |
|
|
|
|
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
|
|
|
|
||||
Operating (loss) income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical Device |
|
$ |
(797 |
) |
|
$ |
(1,902 |
) |
|
$ |
4,683 |
|
|
$ |
(3,246 |
) |
|
|
|
|
In Vitro Diagnostics |
|
|
3,363 |
|
|
|
2,456 |
|
|
|
13,770 |
|
|
|
11,771 |
|
|
|
|
|
Total segment operating income |
|
|
2,566 |
|
|
|
554 |
|
|
|
18,453 |
|
|
|
8,525 |
|
|
|
|
|
Corporate |
|
|
(3,055 |
) |
|
|
(2,547 |
) |
|
|
(11,750 |
) |
|
|
(9,776 |
) |
|
|
|
|
Total (loss) income from operations |
|
$ |
(489 |
) |
|
$ |
(1,993 |
) |
|
$ |
6,703 |
|
|
$ |
(1,251 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Surmodics, Inc. and Subsidiaries Reconciliation of GAAP Measures to Non-GAAP Amounts Schedule of EBITDA, Adjusted EBITDA and Cash Flows from Operations (in thousands) (Unaudited) |
|||||||||||||||
|
Three Months Ended |
|
|
Fiscal Year Ended |
|
||||||||||
|
September 30, |
|
|
September 30, |
|
||||||||||
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Net (loss) income |
$ |
(289 |
) |
|
$ |
(2,946 |
) |
|
$ |
4,237 |
|
|
$ |
1,123 |
|
Income tax (benefit) provision |
|
(273 |
) |
|
|
868 |
|
|
|
2,109 |
|
|
|
(2,577 |
) |
Depreciation and amortization |
|
2,407 |
|
|
|
1,873 |
|
|
|
8,017 |
|
|
|
7,263 |
|
Investment income, net |
|
(28 |
) |
|
|
(72 |
) |
|
|
(123 |
) |
|
|
(656 |
) |
Interest expense |
|
132 |
|
|
|
34 |
|
|
|
310 |
|
|
|
133 |
|
EBITDA |
|
1,949 |
|
|
|
(243 |
) |
|
|
14,550 |
|
|
|
5,286 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquisition transaction, integration and other costs (1) |
|
588 |
|
|
|
— |
|
|
|
1,049 |
|
|
|
— |
|
CARES Act Employee Retention Credit (2) |
|
(3,577 |
) |
|
|
— |
|
|
|
(3,577 |
) |
|
|
— |
|
Loss on strategic investment (3) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
479 |
|
Adjusted EBITDA |
$ |
(1,040 |
) |
|
$ |
(243 |
) |
|
$ |
12,022 |
|
|
$ |
5,765 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Cash Provided by Operating Activities |
$ |
889 |
|
|
$ |
1,314 |
|
|
$ |
15,389 |
|
|
$ |
14,010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Guidance Reconciliation: Estimated Non-GAAP Diluted Earnings Per Share For the Fiscal Year Ending September 30, 2022 (Unaudited) |
|||||||||
|
|
Fiscal 2022 Full-Year Estimate |
|
||||||
|
|
Low |
|
|
High |
|
|||
GAAP diluted EPS |
|
$ |
(2.05 |
) |
|
$ |
(1.55 |
) |
|
Amortization of acquired intangibles per diluted share (4) |
|
|
0.30 |
|
|
|
0.30 |
|
|
Non-GAAP diluted EPS |
|
$ |
(1.75 |
) |
|
$ |
(1.25 |
) |
|
Surmodics, Inc., and Subsidiaries Net Loss and Diluted EPS GAAP to Non-GAAP Reconciliation (in thousands, except per share data) (Unaudited) |
||||||||||||||||||||||||||||
|
|
For the Three Months Ended September 30, 2021 |
|
|||||||||||||||||||||||||
|
|
Total
|
|
|
Operating
|
|
|
Operating
|
|
|
Loss
|
|
|
Net
|
|
|
Diluted
|
|
|
Effective
|
|
|||||||
GAAP |
|
$ |
23,971 |
|
|
$ |
(489 |
) |
|
|
(2.0 |
)% |
|
$ |
(562 |
) |
|
$ |
(289 |
) |
|
$ |
(0.02 |
) |
|
|
48.6 |
% |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of acquired intangible assets (4) |
|
|
— |
|
|
|
1,117 |
|
|
|
4.7 |
% |
|
|
1,117 |
|
|
|
1,014 |
|
|
|
0.07 |
|
|
|
|
|
Acquisition transaction, integration and other costs (1) |
|
|
— |
|
|
|
588 |
|
|
|
2.4 |
% |
|
|
588 |
|
|
|
554 |
|
|
|
0.04 |
|
|
|
|
|
CARES Act Employee Retention Credit (2) |
|
|
— |
|
|
|
(3,577 |
) |
|
|
(14.9 |
)% |
|
|
(3,577 |
) |
|
|
(2,617 |
) |
|
|
(0.19 |
) |
|
|
|
|
Non-GAAP |
|
$ |
23,971 |
|
|
$ |
(2,361 |
) |
|
|
(9.8 |
)% |
|
$ |
(2,434 |
) |
|
$ |
(1,338 |
) |
|
$ |
(0.10 |
) |
|
|
45.0 |
% |
|
|
For the Three Months Ended September 30, 2020 |
|
|||||||||||||||||||||||||
|
|
Total
|
|
|
Operating
|
|
|
Operating
|
|
|
Loss
|
|
|
Net
|
|
|
Diluted
|
|
|
Effective
|
|
|||||||
GAAP |
|
$ |
22,543 |
|
|
$ |
(1,993 |
) |
|
|
(8.8 |
)% |
|
$ |
(2,078 |
) |
|
$ |
(2,946 |
) |
|
$ |
(0.22 |
) |
|
|
(41.8 |
)% |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of acquired intangible assets (4) |
|
|
— |
|
|
|
547 |
|
|
|
2.4 |
% |
|
|
547 |
|
|
|
517 |
|
|
|
0.04 |
|
|
|
|
|
Non-GAAP |
|
$ |
22,543 |
|
|
$ |
(1,446 |
) |
|
|
(6.4 |
)% |
|
$ |
(1,531 |
) |
|
$ |
(2,429 |
) |
|
$ |
(0.18 |
) |
|
|
(58.7 |
)% |
Surmodics, Inc., and Subsidiaries Net Income and Diluted EPS GAAP to Non-GAAP Reconciliation (in thousands, except per share data) (Unaudited) |
||||||||||||||||||||||||||||
|
|
Fiscal Year Ended September 30, 2021 |
|
|||||||||||||||||||||||||
|
|
Total
|
|
|
Operating
|
|
|
Operating
|
|
|
Income
|
|
|
Net
|
|
|
Diluted
|
|
|
Effective
|
|
|||||||
GAAP |
|
$ |
105,136 |
|
|
$ |
6,703 |
|
|
|
6.4 |
% |
|
$ |
6,346 |
|
|
$ |
4,237 |
|
|
$ |
0.30 |
|
|
|
33.2 |
% |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of acquired intangible assets (4) |
|
|
— |
|
|
|
2,793 |
|
|
|
2.7 |
% |
|
|
2,793 |
|
|
|
2,600 |
|
|
|
0.19 |
|
|
|
|
|
Acquisition transaction, integration and other costs (1) |
|
|
— |
|
|
|
1,049 |
|
|
|
1.0 |
% |
|
|
1,049 |
|
|
|
1,015 |
|
|
|
0.07 |
|
|
|
|
|
CARES Act Employee Retention Credit (2) |
|
|
— |
|
|
|
(3,577 |
) |
|
|
(3.5 |
)% |
|
|
(3,577 |
) |
|
|
(2,617 |
) |
|
|
(0.19 |
) |
|
|
|
|
Non-GAAP |
|
$ |
105,136 |
|
|
$ |
6,968 |
|
|
|
6.6 |
% |
|
$ |
6,611 |
|
|
$ |
5,235 |
|
|
$ |
0.37 |
|
|
|
20.8 |
% |
|
|
Fiscal Year Ended September 30, 2020 |
|
|||||||||||||||||||||||||
|
|
Total
|
|
|
Operating
|
|
|
Operating
|
|
|
(Loss)
|
|
|
Net
|
|
|
Diluted
|
|
|
Effective
|
|
|||||||
GAAP |
|
$ |
94,864 |
|
|
$ |
(1,251 |
) |
|
|
(1.3 |
)% |
|
$ |
(1,454 |
) |
|
$ |
1,123 |
|
|
$ |
0.08 |
|
|
|
177.2 |
% |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization of acquired intangible assets (4) |
|
|
— |
|
|
|
2,218 |
|
|
|
2.3 |
% |
|
|
2,218 |
|
|
|
2,076 |
|
|
|
0.15 |
|
|
|
|
|
Loss on strategic investment (3) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
479 |
|
|
|
378 |
|
|
|
0.03 |
|
|
|
|
|
Discrete tax impact of CARES Act (5) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,768 |
) |
|
|
(0.13 |
) |
|
|
|
|
Non-GAAP |
|
$ |
94,864 |
|
|
$ |
967 |
|
|
|
1.0 |
% |
|
$ |
1,243 |
|
|
$ |
1,809 |
|
|
$ |
0.13 |
|
|
|
(45.5 |
)% |
(1) |
Represents expenses specifically associated with the business acquisition of Vetex Medical Limited and associated tax impact. A significant proportion of the acquisition expenses are not tax deductible. |
(2) |
Represents the benefit recorded as a result of the employee retention credit that the Company filed for under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") enacted in March 2020. The estimated tax impact reflects the combined impact of the statutory tax rate of 21% and a reduction in research and development tax credits. |
(3) |
In fiscal 2020, represents the loss recognized on the impairment of a strategic investment and associated tax impact. |
(4) |
Amortization of business acquisition-related intangible assets and associated tax impact. A significant portion of the business acquisition-related amortization is not tax deductible. |
(5) |
Represents the discrete income tax benefit recognized in fiscal 2020 from the carryback of net operating losses under the provisions of the CARES Act. |
(6) |
Net (loss) income includes the effect of the above adjustments on the income tax benefit (provision), taking into account deferred taxes and non-deductible items. Income tax impacts were estimated using the applicable statutory rate (21% in the U.S. and 12.5% in Ireland). |
(7) |
Potentially dilutive common shares resulting from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units have been excluded from the calculation of GAAP net loss per share as their effect was antidilutive for three months ended September 30, 2021 and 2020 as a result of the GAAP net loss for these periods. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005421/en/
Contacts
Surmodics, Inc.
Tim Arens, 952-500-7000
ir@surmodics.com
